FPAS
RGNX icon

Focus Partners Advisor Solutions’s Regenxbio RGNX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,676
Closed -$183K – 1342
2025
Q4 		$183K Buy
12,676
+2,455
+24% +$30.6K ﹤0.01% 1036
2025
Q3 		$107K Buy
+10,221
New +$90.4K ﹤0.01% 1095

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Focus Partners Advisor Solutions's RGNX Position: Q1 2026 in Review

Focus Partners Advisor Solutions sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 12,676 shares — an estimated $183K sold.

Focus Partners Advisor Solutions first reported a position in RGNX in Q3 2025 and held it in 2 quarters. The position peaked at $183K in Q4 2025. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Focus Partners Advisor Solutions reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Advisor Solutions sold 12,676 Regenxbio shares in Q1 2026, an estimated $183K.
  • Focus Partners Advisor Solutions first reported a position in Regenxbio in Q3 2025 and held it in 2 quarters.
  • Focus Partners Advisor Solutions's Regenxbio position peaked at $183K in Q4 2025.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.